SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) was the target of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 31,402 shares, an increase of 407.1% from the July 30th total of 6,193 shares. Based on an average daily trading volume, of 52,642 shares, the short-interest ratio is currently 0.6 days.
SAB Biotherapeutics Trading Down 7.6%
SABSW stock traded down $0.00 during mid-day trading on Thursday, hitting $0.03. 15,543 shares of the company were exchanged, compared to its average volume of 80,919. The business has a 50 day simple moving average of $0.02 and a 200-day simple moving average of $0.02. SAB Biotherapeutics has a 1-year low of $0.00 and a 1-year high of $0.20.
SAB Biotherapeutics Company Profile
SAB Biotherapeutics, Inc is a clinical-stage biopharmaceutical company specializing in the development of fully human polyclonal antibody therapeutics. The company’s core technology, known as the Transchromosomic (Tc) Bovine platform, leverages genetically engineered cattle to produce large volumes of human antibodies in response to targeted antigens. These antibodies are designed to treat a range of infectious diseases and immunological disorders, offering a complementary approach to monoclonal antibodies and traditional vaccines.
The company’s lead programs focus on combating high-priority pathogens, including emerging coronaviruses and other viral threats.
See Also
- Five stocks we like better than SAB Biotherapeutics
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for SAB Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAB Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
